Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ:AMGN)

280.75 +0.91 (+0.33%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Amgen

< Previous 1 2 3 4 5 Next >
Why These 3 Equal-Weighted ETFs Deserve a Portfolio Spot
These three equally-weighted exchange traded funds that offer superior diversification and risk adjusted returns are worth a look. 
Via MarketBeat
Topics ETFs
Prescriptions for Portfolio Health: 3 Resilient Healthcare Stocks
During the peak of the recent selloff, the healthcare sector outshone, with three stocks showing resilience and impressive upward moves. 
Via MarketBeat
Topics ETFs
Argenx's 28% Surge & Promising Product Propel Investor Confidence
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target. 
Via MarketBeat
Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 22, 2023 – USA News Group – Despite the potential federal funding challenges due to the recent debt ceiling deal,... 
Via FinancialNewsMedia
Amgen Inc. (NASDAQ: AMGN) is a Leading Gainer in Tuesday Morning Trading
Via Investor Brand Network
Flee to Healthcare Stocks if Recession Rears its Head?
In uncertain economic conditions, healthcare stocks can be a refuge due to steady demand and favorable inflation conditions. Many also offer dividends. 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
3 Growth Stocks to Buy in September
As the calendar turns to September, optimistic investors will look for value in quality companies with a history of generating strong revenue and earnings 
Via MarketBeat
Topics Economy
Exposures Economy
Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition
From Horizon Therapeutics plc and Amgen
Via Business Wire
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?
Pharmaceutical stocks are holding steady as Medicare price negotiations approach, but industry diversification and innovation support future growth prospects. 
Via MarketBeat
Topics Economy
Exposures Interest Rates
Amgen Inc. (NASDAQ: AMGN) is a Leading Gainer in Tuesday Morning Trading
Via Investor Brand Network
Mind Science Targeting Big Brains and Portfolios
Via AB Newswire
Drinks, Chips & Drugs: A Surprising List of 10-Year Stock Winners
A handful of large caps have taken things to another level. These three stocks have blown past the herd — and may be market leaders for years to come. 
Via MarketBeat
Topics Bankruptcy Economy
Exposures Economy Financial Legal
Longeveron Announces Key Additions To Its Leadership Team and Board As It Gears Up For Phase 2 Trials For Its Lead Drug Candidate For Several Conditions
By David Willey, Benzinga 
Via TheNewswire.com
Is Growth Priced into Amgen Stock after Earnings Beat?
Amgen earnings delivered a solid earnings report after the market closed but analyst sentiment suggests that growth may already be priced into AMGN stock. 
Via MarketBeat
INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates Amgen Inc’s Directors and Officers for Breach of Fiduciary Duties – AMGN
From Scott+Scott Attorneys at Law LLP
Via Business Wire
Lilly Shares Up On Versanis Deal Amid Weight-Loss Drug Gold Rush
A bid to acquire Versanis boosts Eli Lilly & Co. by 2.80% in the past week, as the competition to develop the most effective weight-loss drug intensifies. 
Via MarketBeat
Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus
Regulatory filings show Gilead Sciences' purchase of shares in AlloVir and Arcus. Strategic investments in the biotech sector are fairly common to boost growth. 
Via MarketBeat
Topics Retirement
Exposures Pension
Activision Surges 10% As Judge OK's Microsoft Acquisition Deal
Following a federal judge's OK of Microsoft's acquisition, Activision shares soared 10%, marking their strongest performance in over a year. The FTC can appeal. 
Via MarketBeat
Activision Blizzard Shares up 1.83% Amid Regulators' Blunders
Shares of Microsoft Corp. (NASDAQ: MSFT) declined 1.92% on June 26, more than the broader market, while Activision Blizzard Inc. (NASDAQ: ATVI) rose 1.83%. The S&P 500 declined 0.41% in the session. 
Via MarketBeat
Topics Stocks
Exposures US Equities
Is the Biotech Industry (IBB) Poised For A Major Breakout?
The current consolidation in the IBB signals a potential breakout might be looming as key moving averages have converged within a contracted price range. 
Via MarketBeat
Topics ETFs
3 Stocks Worth Buying at 52-Week Lows
Here are three stocks that are trading near their 52-week lows and may be primed for a short-term rally for opportunistic investors 
Via MarketBeat
Is Pfizer's Seagen Deal In Jeopardy Amid Antitrust Scrutiny?
Despite worries about FTC scrutiny, Pfizer remains optimistic about its planned Seagen acquisition, issuing $31 billion in bonds to finance the deal. 
Via MarketBeat
Topics Bonds
Exposures Debt Markets
Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings
Vertex Pharmaceuticals hits record high on strong earnings, FDA approval for cystic fibrosis medication for infants. Analysts recently boosted price targets. 
Via MarketBeat
Exposures Product Safety
The Turnaround for Weight Watchers is Taking Shape
Weight management meals and services provider WW International Inc. (NYSE: WW) stock made a 52-week high of $10.02 after its Q1 2023 earnings release. Shares 
Via MarketBeat
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amgen Inc. (AMGN)
From The Law Offices of Frank R. Cruz
Via Business Wire
AMGEN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Amgen Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
NASDAQ:AMGN Investor Notice: Deadline on May 12, 2023 in Lawsuit Against Amgen Inc. Coming Up
San Diego, CA -- (SBWIRE) -- 05/10/2023 -- The Shareholders Foundation announced that a deadline is coming up on May 12, 2023 in the lawsuit filed for certain investors of Amgen Inc. (NASDAQ:AMGN). 
Via SBWire
TScan Therapeutics (NASDAQ: TCRX) and Amgen (NASDAQ: AMGN) Join Forces to Battle Crohn’s Disease
TScan Therapeutics, Inc. (NASDAQ: TCRX) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development 
Via Spotlight Growth
Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohn’s Disease
From TScan Therapeutics, Inc.
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against SVB, Amgen, and Signature and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.